Impact of UGT2B7 His268Tyr Polymorphism on the Outcome of Adjuvant Epirubicin Treatment in Breast Cancer

Breast Cancer Research - United Kingdom
doi 10.1186/bcr2894
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Association of TP53codon 72 Polymorphism and the Outcome of Adjuvant Therapy in Breast Cancer Patients

Breast Cancer Research
Cancer ResearchOncology
2007English

Weekly Epirubicin in the Treatment of Gestational Breast Cancer (GBC)

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

Adjuvant Bisphosphonates in Breast Cancer Treatment

Breast Care
SurgeryOncology
2014English

Taxanes in Adjuvant Breast Cancer Treatment

Libri Oncologici
Oncology
2018English

Impact of Neoadjuvant Chemotherapy on Breast Cancer Biomarkers: A Guide for Further Adjuvant Treatment

Cancer Research Journal
2019English

Polymorphism in Glutathione S-Transferase P1 (GSTP1) on the Effect of Epirubicin or Doxorubicin Chemotherapy Among Breast Cancer

African Journal of Pharmacy and Pharmacology
2013English

Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer

New England Journal of Medicine
Medicine
2006English

Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment

Clinical Drug Investigation
MedicinePharmacology
2017English

Adjuvant Treatment for Breast Cancer: The Overview.

BMJ
1992English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy